Baird Says No Change to Sarepta (SRPT) Outlook Amid Anthem Slight

October 7, 2016 1:06 PM EDT
Get Alerts SRPT Hot Sheet
Price: $30.74 -2.13%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade SRPT Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst Brian Skorney said their is no change to his outlook on Sarepta Therapeutic (NASDAQ: SRPT) amid news Anthem, the nation's second-largest insurer by number of covered lives, issued a coverage policy this morning categorizing Exondys 51 as "not medically necessary."

"We want to caution reading too much into this coverage decision, as this does not mean that Anthem is not covering the drug," the analyst said. "So far, the nation's other large insurers (United, Cigna, Humana) appear to have favorable coverage for the drug."

The firm reiterated an Outperform rating and price target of $102 on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $61.74 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities

Robert W Baird

Add Your Comment